Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, James N. Kochenderfer, Jesús G. Berdeja et al.|New England Journal of Medicine|2019Cited by 1.7k
Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editingBenjamin P. Kleinstiver, J. Keith Joung, Alexander A. Sousa et al.|Nature Biotechnology|2019Cited by 724
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studiesReuben Benjamin, Jackie Chappell, Nicolas Ferry et al.|The Lancet|2020Cited by 358
Catch me if you can: Leukemia Escape after CD19-Directed T Cell ImmunotherapiesMarco Ruella, Marcela V. Maus|Computational and Structural Biotechnology Journal|2016Cited by 281
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomideMax Jan, Benjamin L. Ebert, Irene Scarfò et al.|Science Translational Medicine|2021Cited by 257